The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
Nanotechnology-based mRNA vaccines
Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …
precise immune responses against infectious diseases and cancers. Compared with …
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
To elicit optimal immune responses, messenger RNA vaccines require intracellular delivery
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
E Kon, N Ad-El, I Hazan-Halevy… - Nature reviews clinical …, 2023 - nature.com
Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …
ongoing research area that started before these versatile nanoparticles were successfully …
Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics
Several studies have utilized a lipid nanoparticle delivery system to enhance the
effectiveness of mRNA therapeutics and vaccines. However, these nanoparticles are …
effectiveness of mRNA therapeutics and vaccines. However, these nanoparticles are …
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid
nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of …
nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of …
Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70
Messenger RNA (mRNA) vaccines were pivotal in reducing severe acute respiratory
syndrome 2 (SARS-CoV-2) infection burden, yet they have not demonstrated robust …
syndrome 2 (SARS-CoV-2) infection burden, yet they have not demonstrated robust …
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
A Barmada, J Klein, A Ramaswamy, NN Brodsky… - Science …, 2023 - science.org
Rare immune-mediated cardiac tissue inflammation can occur after vaccination, including
after SARS-CoV-2 mRNA vaccines. However, the underlying immune cellular and molecular …
after SARS-CoV-2 mRNA vaccines. However, the underlying immune cellular and molecular …
The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology
During the COVID-19 pandemic, mRNA (mRNA) vaccines emerged as leading vaccine
candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) …
candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) …
mRNA vaccines for cancer immunotherapy
YL Vishweshwaraiah, NV Dokholyan - Frontiers in immunology, 2022 - frontiersin.org
Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA
vaccines are an attractive and powerful immunotherapeutic platform against cancer because …
vaccines are an attractive and powerful immunotherapeutic platform against cancer because …